Responses to parliamentary questions
Question from Deputy Ken O’Flynn - PQ 39833-26
Deputy O'Flynn asked about the reimbursement of omaveloxolone (skyclarys). Read the HSE response.
From: Communications and public affairs
Published: May 2026
Updated: July 2026
Documents
Question from Deputy Ken O’Flynn - PQ 39833-26
PDF, 468KB, 3 pages
Summary
To ask the Minister for Health whether any orphan-drug specific weighting, modified cost-effectiveness threshold, severity adjustment or rare disease reimbursement framework was applied in the assessment of omaveloxolone (skyclarys); and if she will make a statement on the matter.
This is a beta version - your feedback will help us to improve it